| 6.01 0.09 (1.52%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.29 | 1-year : | 8.52 |
| Resists | First : | 6.25 | Second : | 7.29 |
| Pivot price | 5.7  |
|||
| Supports | First : | 5.63 | Second : | 5.25 |
| MAs | MA(5) : | 5.97 |
MA(20) : | 5.64 |
| MA(100) : | 6.74 |
MA(250) : | 6.48 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 74.3 |
D(3) : | 77.9 |
| RSI | RSI(14): 53.1 |
|||
| 52-week | High : | 10.07 | Low : | 3.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XERS ] has closed below upper band by 21.1%. Bollinger Bands are 17.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.06 - 6.08 | 6.08 - 6.11 |
| Low: | 5.7 - 5.72 | 5.72 - 5.75 |
| Close: | 5.97 - 6.01 | 6.01 - 6.05 |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Wed, 08 Apr 2026
XERS.O Technical Analysis & Stock Price Forecast - Intellectia AI
Wed, 08 Apr 2026
XERS Should I Buy - Intellectia AI
Wed, 08 Apr 2026
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Q4 2025 Earnings Beat - Sahm
Tue, 07 Apr 2026
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? - MSN
Sat, 04 Apr 2026
Q1 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
Fri, 03 Apr 2026
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 172 (M) |
| Shares Float | 164 (M) |
| Held by Insiders | 3.8 (%) |
| Held by Institutions | 59.2 (%) |
| Shares Short | 16,220 (K) |
| Shares Short P.Month | 17,390 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | 0.1 % |
| Operating Margin | 19.5 % |
| Return on Assets (ttm) | 4.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 42.7 % |
| Gross Profit (p.s.) | 1.44 |
| Sales Per Share | 1.69 |
| EBITDA (p.s.) | 0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 29 (M) |
| Levered Free Cash Flow | 26 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 75.12 |
| Price to Sales | 3.55 |
| Price to Cash Flow | 36.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|